Tocilizumab in the Treatment of Juvenile Rheumatoid Arthritis

Abstract

In the development of rheumatic diseases, especially juvenile rheumatoid arthritis, the important role of some cytokines, most important of which are interleukin-1, interleukin-6 and tumor necrosis factor α, has been proved. A step forward in the treatment of this group of diseases is immunobiological products. The preparation of humanized anti-interleukin-6 receptor antibodies tocilizumab is highly effective and safe agent for the treatment of systemic and polyarticular forms of juvenile rheumatoid arthritis.

Keywords

• juvenile rheumatoid arthritis
• treatment
• tocilizumab.